- Home
- PGEN vs ITOS Comparison
PGEN vs ITOS Comparison
Compare PGEN & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PGEN
- ITOS
- Stock Information
- Founded
- PGEN 1998
- ITOS 2011
- Country
- PGEN United States
- ITOS United States
- Employees
- PGEN N/A
- ITOS N/A
- Industry
- PGEN Biotechnology: Pharmaceutical Preparations
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PGEN Health Care
- ITOS Health Care
- Exchange
- PGEN Nasdaq
- ITOS Nasdaq
- Market Cap
- PGEN 292.6M
- ITOS 283.9M
- IPO Year
- PGEN N/A
- ITOS 2020
- Fundamental
- Price
- PGEN $0.76
- ITOS $7.30
- Analyst Decision
- PGEN Buy
- ITOS Strong Buy
- Analyst Count
- PGEN 5
- ITOS 3
- Target Price
- PGEN $7.00
- ITOS $21.33
- AVG Volume (30 Days)
- PGEN 1.1M
- ITOS 535.6K
- Earning Date
- PGEN 11-14-2024
- ITOS 11-12-2024
- Dividend Yield
- PGEN N/A
- ITOS N/A
- EPS Growth
- PGEN N/A
- ITOS N/A
- EPS
- PGEN N/A
- ITOS N/A
- Revenue
- PGEN $3,963,000.00
- ITOS $35,000,000.00
- Revenue This Year
- PGEN N/A
- ITOS $271.18
- Revenue Next Year
- PGEN $402.12
- ITOS N/A
- P/E Ratio
- PGEN N/A
- ITOS N/A
- Revenue Growth
- PGEN N/A
- ITOS N/A
- 52 Week Low
- PGEN $0.65
- ITOS $7.09
- 52 Week High
- PGEN $1.93
- ITOS $18.75
- Technical
- Relative Strength Index (RSI)
- PGEN 43.22
- ITOS 29.34
- Support Level
- PGEN $0.76
- ITOS $7.44
- Resistance Level
- PGEN $0.78
- ITOS $7.96
- Average True Range (ATR)
- PGEN 0.06
- ITOS 0.38
- MACD
- PGEN -0.00
- ITOS -0.07
- Stochastic Oscillator
- PGEN 34.93
- ITOS 5.41
About PGEN Precigen Inc.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.